Schizo_Bin {Surrogate}R Documentation

Data of a clinical trial in Schizophrenia (with binary outcomes).

Description

These are the data of a clinical trial in Schizophrenia (a subset of the dataset Schizo_Bin, study 11 where the patients were administered 1010 mg. of haloperidol or 88 mg. of risperidone). A total of 454454 patients were treated by 117117 investigators (psychiatrists). Patients' schizophrenia symptoms at baseline and at the end of the study (after 88 weeks) were measured using the PANSS and BPRS. The variables BPRS_Bin and PANSS_Bin are binary outcomes that indicate whether clinically meaningful change had occurred (1 = a reduction of 2020% or higher in the PANSS/BPRS scores at the last measurement compared to baseline; 0 = no such reduction; Leucht et al., 2005; Kay et al., 1988).

Usage

data(Schizo_Bin)

Format

A data.frame with 454454 observations on 55 variables.

Id

The patient ID.

InvestI

The ID of the investigator (psychiatrist) who treated the patient.

Treat

The treatment indicator, coded as 1-1 = control treatment (10 mg. haloperidol) and 11 = experimental treatment (8 mg. risperidone).

PANSS_Bin

The dichotomized change in the PANSS score (1 = a reduction of 2020% or more in the PANSS score, 0=otherwise)

BPRS_Bin

The dichotomized change in the BPRS score (1 = a reduction of 2020% or more in the BPRS score, 0=otherwise)

CGI_Bin

The sichtomized change in the CGI score, coded as 11 = a change of more than 33 points on the original scale (score at the end of the treatment relative to score at the beginning of the treatment), 00 = otherwise.

References

Kay, S.R., Opler, L.A., & Lindenmayer, J.P. (1988). Reliability and validity of the Positive and Negative Syndrome Scale for schizophrenics. Psychiatric Research, 23, 99-110.

Leucht, S., et al. (2005). Clinical implications of Brief Psychiatric Rating Scale scores. The British Journal of Psychiarty, 187, 366-371.


[Package Surrogate version 3.3.0 Index]